Skip to main content

INES: Interactive tool for construction and extrapolation of partitioned survival models



INES (INteractive model for Extrapolation of Survival and cost) provides an open-access tool powered by R that implements three-state partitioned survival models (PSM). This article describes the properties of the tool, and the situations where INES may or may not be suitable.


INES is designed to be used by investigators or healthcare professionals who have a good grasp of the principles of economic evaluation and understand the strengths and weaknesses of partitioned survival models, but are not sufficiently familiar with a statistical package such as Excel or R to be able to construct and test a de-novo PSM themselves.

INES is delivered to the user via a batch file. Once downloaded to the user’s hard drive, it interacts with the user via a portable version of R with web interactivity built in Shiny. INES requires absolutely no knowledge of R and the user does not need to have R or any of its dependences installed. Hence the user will deal with a standalone Shiny app. Inputs (digitalized survival curves, unit costs, posology, hazard ratios, discount rate) can be uploaded from a template spreadsheet.


The INES application provides a seamlessly integrated package for estimating a set of parametric hazard functions for progression free and overall survival, selecting an appropriate function from this menu, and applying this as an input to a PSM to calculate mean costs and quality-adjusted life years. Examples are given that may serve as a tutorial.


INES offers a rapid, flexible, robust and transparent tool for parametric survival analysis and calculating a PSM that can be used in many different contexts.


Models are decision tools commonly used for the economic evaluation of health care technologies. In general terms, the model framework might be configured in several ways including decision tree, partitioned survival model (PSM), state-transition (Markov cohort) model, or event -based simulation [1]. This article presents a new open-access modelling tool for PSM: INES (INteractive model for Extrapolation of Survival and cost).

The process of constructing a PSM usually requires three fundamental steps. First, the individual patient data (IPD) must be available from a clinical study containing duration of overall survival (OS) and progression-free survival (PFS) in the intervention and control group. However, IPD are often not available to the researcher. Hence the first step in these situations consists of recreating the IPD from the coordinates of published OS and PFS Kaplan–Meier curves using a statistical algorithm, a process known as “digitalization” of the survival curves. The second step is to estimate a set of parametric functions fitted to the IPD, and for the user to select the most appropriate function (we discuss possible criteria in the Methods). The third step is to estimate mean costs and mean (quality-adjusted) life years over a chosen time horizon. In a PSM this is achieved extrapolating the survival functions over the model time horizon, dividing the analysis time into short model cycles, applying cost weights, utility weights and a discount factor to the proportion of the initial cohort in each state in each cycle, and numerically integrating over the model time horizon to obtain the areas under the curves.

There are several existing packages available to conduct the final step in a PSM analysis, such as TreeAge®, R packages [2], or the user could construct a de-novo model in Excel or R. These options vary in the degree of technical and programming expertise required of the user. However, all of these software options start from the premise that the user will provide the package with the parametric survival functions as inputs. In other words, existing PSM packages take for granted that the user has successfully accomplished the first two steps. This poses a steep learning curve and may be a barrier to many practitioners.

INES is designed to be used by investigators who have a good grasp of the principles of economic evaluation and understand the strengths and weaknesses of partitioned survival models, but do not have the time, statistical background or programming expertise to conduct all these steps for a PSM themselves. It offers a rapid, flexible, robust tool that brings together these modules in a single, seamless package. This article describes the properties of the tool, and discusses the situations where it may or may not be suitable. This article illustrates the tool using a particular case for demonstration purposes but we do not make any statement here about the appropriateness of these specific modelling choices or the cost-effectiveness of particular therapies.


INES is delivered to the user via a batch file, available from [3]. Once downloaded to the user’s hard drive, it interacts with the user via a portable version of R (v. 4.1.3), with web interactivity built in Shiny [4]. INES requires no knowledge of R and the user does not need to have R or any of its dependencies installed (in practice, the user will deal with a standalone Shiny app). INES can be run on Windows (7, 8, 10 and 11), Mac and Linux. The tool is available free of charge and under a creative commons attribution license (CC BY).

Once downloaded and extracted to a folder on the user’s hard drive, INES is initiated by selecting “run.bat” from the folder. Data are input via a spreadsheet template provided in the batch file. Once data are inputted, run time is a few seconds.

INES is designed to accomplish the tasks summarized in Table 1 and described in more detail in the following sections. The PSM as enacted in INES estimates the proportion of the cohort in each of 3 states (labelled progression-free, progressed and dead) using two survival curves (PFS and OS), where the difference represents the time post-progression (PPS). The terms progression-free and progressed are for convenience: fundamentally a PSM assumes that backward transitions are not allowed. Patients receive the intervention of interest at the start of the model or during the PFS state and may employ another treatment during the next state. Quality of life (utility) and cost weights are associated with the time in the progression-free and post-progression states [5]. INES compares two alternative therapies. In this article they will be termed “intervention” and “comparator” or “control”. Users are guided through the steps required by an interactive dashboard (Fig. 1). The model cycle length in INES is one month, and this cannot be altered. Data can be uploaded via a spreadsheet template, described in Table 2. Table 3 justifies the modelling choices built into INES.

Table 1 Functionality of the INES tool
Fig. 1
figure 1


Table 2 Data required by the INES tool
Table 3 Model choices in INES and possible alternative configurations of a PSM

Digitization of the Kaplan–Meier survival curves

INES requires as input the numerical coordinates of the Kaplan–Meier survival curves (the probability of OS and PFS state membership at each month). These can be digitized from publications using software such as WebPlotDigitizer (the website provides manuals and video tutorials [6]). These coordinates must be accompanied by the numbers at risk and, if available, the aggregate number of events. Behind the scenes, the INES tool uses a published R algorithm to map the digitized curves back to the original individual patient data (IPD), the time at which events occurred or censoring occurred [7, 8]. INES in its current configuration does not accept the original IPD as input.

Estimation of parametric survival functions in the control group

A PSM model requires as an input a parametric survival function for PFS and OS. Parametric functions are recommended because published PFS or OS survival curves in clinical studies are rarely complete. For example, many therapies gain marketing authorization before even half of the patients in the study have died. Notwithstanding, economic evaluation requires an estimation of mean survival time in each state. Even if available, median survival time will not be a suitable proxy for mean survival time if some individuals have long survival times after the median [9]. Hence it is necessary to model and extrapolate the PFS and OS survival curves.

Different parametric functions can make very different predictions about survival, especially in the time after the clinical trial. This is a crucial area of uncertainty in the construction of any PSM. There are several options for how survival might be modelled. Guidelines recommend that the chosen function should approximate both to the observed clinical study data (internal validity), and the investigators’ understanding of the long-term progression or survival of the target population of patients (external validity) [10].

INES is unique among economic evaluation tools as it provides an integrated package that enables the user to estimate a set of parametric hazard functions from observed PFS and OS Kaplan–Meier coordinates, select an appropriate function from this set, and apply this function as an input to a PSM to calculate mean costs and quality-adjusted life years. All the algorithms are handled behind the scenes and the user is not required to manipulate any R commands.

There are 4 survival functions to consider: OS and PFS in each treatment group. In general terms, one could fit independent functional forms to each of the 4 curves, or the same functional form, or permutations thereof [11]. The particular approach taken in INES is to fit parametric survival functions to model survival in the control group, and apply a hazard ratio (HR) to represent the respective survival in the intervention group (Table 3). The INES tool allows the user to choose from one of eight functions: exponential, gamma, log-logistic, Weibull, log-normal, Gompertz, generalized gamma, and generalized-F. Different parametric functions can be chosen for PFS and OS.

The INES tool offers two useful features to help the user choose an appropriate parametric function. First, INES calculates the Akaike Information Criteria (AIC) (Fig. 2). This compares the fit of the observed comparator group data with the predictions of the parametric model. The AIC rewards goodness of fit of the parametric function to the observed data, while penalizing the number of parameters. However, AIC (and similar tests) only measure internal validity, and should be used cautiously. Such tests tell us nothing about the absolute quality of a model, only the relative quality of the candidate parametric functions. The AIC does not provide any warning that all models might fit the data poorly. The AIC also tells us nothing about the ability of the model to predict events that occur after the source data follow-up. The second useful feature provided by INES is a graph of the observed data and the predicted model. This allows the user to visualize the fit of the parametric function with the observed data, and to examine the effect of extrapolating this function over the model time horizon (Fig. 2). The user should seek expert judgement about the plausibility of the chosen model.

Fig. 2
figure 2

a Overall survival and b Progression-Free Survival predicted by the INES tool. Red curve: intervention group. Blue curve: control group. Continuous curve: predicted survival. Intermittent curve: observed survival (Kaplan Meier). AIC Akaike Information Criteria. OS overall survival. PFS Progression Free Survival

Hazard ratio for PFS and OS

The INES tool assumes the hazard ratios for OS and PFS are unchanged over time (proportional hazards, PH). The user can use the spreadsheet template to input hazard ratios for PFS and OS into INES based on published evidence from a clinical study or the literature. Alternatively, the user can request that INES calculates the hazard ratios from the IPD (Cox PH model).

The INES tool uses the apply_hr function from the package HEEMOD to calculate the survival function in the intervention group, given the survival function in the control group and the HR. The apply_hr function multiplies the hazards in the control group by the (constant) HR. This works whether the control group model was estimated by flexsurv using the PH metric (that is, exponential or Gompertz) or the accelerated failure time metric (other models).

Proportional hazards mean that the rate of events (the hazards) in individuals in the intervention arm are a constant multiple of the rate in the control arm. As noted above, the PH assumption is only one of the possible options for modelling survival curves in a PSM and extrapolating beyond the clinical study [10,11,12]. The user must consider whether the PH assumption is appropriate. A visual inspection of the Kaplan–Meier survival curves in each group can be informative. If the survival curves cross, or if the survival curves radically diverge, then this may indicate that hazards may not be proportional. The INES tool also provides a statistical test based on the digitized survival curves [13] (Fig. 2). If the p-value is low (e.g. less than 0.05) then the sample data are not consistent with the null hypothesis of proportional hazards. However, statistical tests are not the only criteria and users must seek expert judgement to assess whether the proportional hazards model is appropriate for modelling and extrapolation in their evaluation. If hazard ratios are not thought to be constant over the model time horizon, then the user should consider using a different tool.

Discount rate

The discount rate ensures that the model takes account of social time preference [14]. The tool uses the same discount rate for costs and benefits, and the value should be input as an annual rate (guidelines usually recommend values between 0 and 0.05 [15]). A range can be employed for univariate sensitivity analysis.

Unit costs

The tool requires users to introduce prices or unit costs of each of the resources employed (see "Resource use" section). A range of values can be employed for univariate sensitivity analysis.

Resource use

The tool allows users to introduce the number of units of resources employed in each treatment group in each health state. These can be doses of medicines, adverse events, diagnostic tests, other healthcare or any other type of resource. The user can express the consumption in any period either at a general level (e.g. 1 unit per month) or at a very granular level (e.g. on specific days). The INES tool will automatically and precisely translate this information into the equivalent consumption during each model cycle.

During the PFS state, INES allows consumption of each resource to vary over time. For example, in the ANDROMEDA trial [16], patients received daratumumab in “treatment cycles” (not to be confused with the “model cycle” which is an entirely different concept). Each treatment cycle in ANDROMEDA lasted 4 weeks. Patients received daratumumab once a week in treatment cycles 1 and 2, every 2 weeks in treatment cycles 3 through 6, and every 4 weeks thereafter until disease progression, the start of subsequent therapy, or for a maximum of 24 treatment cycles from the start of the trial, whichever occurred first. In the clinical study, other therapies were also given in both treatment groups, but are not discussed here for brevity. INES has been designed to be flexible enough to calculate consumption under complex administration regimens such as these. Additional file 1 shows the data input template for this example and gives further explanation of the variables.

Utility weights

The model requires the user to enter three utility parameters: the utility weights in each treatment group during the progression-free state, and a single utility weight during post-progression. The model will calculate life years if the utility weights are 1. A range can be employed for univariate sensitivity analysis. The current version of the tool does not allow utility weights to vary over time, but this might be modified in future versions.

PSM model engine

The model engine for the PSM is implemented by the HEEMOD package in R (Table 1) [17]. The user provides the chosen parametric survival functions for PFS and OS ("Estimation of parametric survival functions in the control group" section), the hazard ratios ("Hazard ratio for PFS and OS" section), the discount rate ("Discount rate" section), resource use quantities and prices of those quantities ("Unit costs" and "Resource use" section) and the utilities ("Utility weights" section). Behind the scenes, HEEMOD then defines the cost and utility weights for the three states (PFS, PPS and dead) (define_state), the strategies (define_strategy) and runs the model (run_model). The probability of membership of the PPS state as the difference between OS and PFS is set up using the define_part_surv function. A half-cycle correction is applied, meaning that events are calculated as if they occur half-way through each month. Univariate sensitivity analyses are conducted using the run_dsa function.

Probabilistic sensitivity analysis (PSA)

The current version of the tool does not implement PSA. While HEEMOD provides a function to implement PSA based on the same variables used in the univariate sensitivity analysis (Table 2: unit costs, hazard ratios, and the discount rate), it does not account in PSA for what is often the principal source of uncertainty, namely the choice of parametric survival function ("Estimation of parametric survival functions in the control group" section). Properly taking account of structural uncertainty is a challenge for any PSM [18]. It is hoped that a future version can provide a means of conducting PSA that takes these factors into account, for example, by model averaging [19]. We suggest in the meantime that the analyst reports deterministic results using different parametric functions.


An example using INES is given based on the Destiny-Breast03 study [20]. This clinical study compared Trastruzumab Deruxtecan (intervention) versus Trastruzumab Emtansine (control) for second-line treatment of advanced HER2 + breast cancer [20]. The clinical study reported Kaplan–Meier curves for PFS and OS up to 34 months, though less than 10% of patients had follow-up beyond 2 years. The reported HR were 0.55 (0.36–0.86) for OS and 0.28 (0.22–0.37) for PFS. A template pre-loaded with the data used in this example can be downloaded from [21].

The INES tool produces interactive graphs comparing the Kaplan–Meier with the user’s parametric choices (Fig. 2). For illustrative purposes, the Weibull was chosen for PFS and OS, and a 100 month time horizon (This article does not comment on the appropriateness of these parameters in this particular case. The reader should consult methodological guidelines [12]). The graph also shows the AIC and the p-value of the test for proportional hazards.

Unit costs and resource use

Trastruzumab Emtansine is administered 3.6 mg/kg once every 3 weeks and Trastruzumab Deruxtecan is administered 5.4 mg/kg, until progression. For a 100 mg unit with no wastage, for a representative 70 kg individual this represents 2.52 units per treatment cycle of Trastruzumab Emtansine (control: treatment = 2) versus 3.78 units per cycle of Trastruzumab Deruxtecan (intervention: treatment = 1). The list price of a 100 mg unit is (approximately) 2720€ for Trastruzumab Emtansine and 2194€ for Trastruzumab Deruxtecan. The costs per month were coded in the format shown in Additional file 2 assuming a lower bound for prices of 50% of list price. Values are shown here for illustration only and have no bearing with real prices that might be paid.

The costs of a hypothetical subsequent therapy after progression are captured in the parameter “next_line”. This is valued as zero in the base case, and 3000€ per month as a sensitivity analysis.

Estimate of mean costs and effects

INES reports predictions of survival (Additional file 3), undiscounted and discounted means of life years, costs and QALY (or LY if utilities are 1) (Additional file 4). In this case, the ICER is 248,409€ per incremental life year.

Univariate sensitivity analyses

INES produces a tornado chart (Additional file 5). Users can select which variables to include or exclude from the display. All charts and graphs can be downloaded as images from the application to the user’s hard drive.


INES provides a tool for users who are knowledgeable about the disease area, the evidence base and the principles of economic evaluation but do not have the time or programming expertise to construct and validate a de novo model. Existing R commands and packages are available to recreate IPD from the Kaplan–Meier coordinates, fit parametric survival functions to these IPD, and construct a PSM with these survival functions. However, taken together, they demand a high level of technical skill and time. INES integrates all these features in a single application that interacts with the user via their browser, without requiring any knowledge by the user of the underlying R commands. INES is unique in this important regard.

INES was designed to offer powerful functionality, previously accessible only to computer programming specialists, and at the same time to be simple to use. The need to integrate the various modules in a single application meant that certain parameters were fixed deliberately in the construction of INES and so cannot be altered by the user. The following paragraphs discuss these and other limitations.

INES implements a PSM with three states. There are a few examples of PSM with four states [22], but three states is the most common configuration for practical purposes [5]. The cycle length is fixed at one month. This need not be a severe limitation for most applications, as the resource use can be defined at very granular intervals.

PSM have been widely used in health technology assessment, particularly in late stage and metastatic cancer. Their popularity has been attributed their simplicity of structure, their frugal demand for input data, and the ability to directly compare results to the source clinical study [5]. Their weaknesses are also well documented. A PSM is mainly descriptive, that is, it does not incorporate an explanation of how a treatment achieves its results. In principle, a treatment that delays disease progression might be expected to delay death, but (unlike a Markov model) a PSM does not parameterize this conditional probability. Survival and PFS in a PSM are modelled  as if they were independent variables.

Models such as PSM are often desirable to extrapolate survival and estimate costs when clinical trial data do not follow up all participants until death [23]. A PSM is usually appropriate when the extrapolation is over a moderate time horizon beyond that of the source clinical study. Over a much longer time horizon, other variables not captured by the clinical study data will influence outcomes (such as mortality related to old age) [24]. In such situations, a Markov model or discrete event simulation may be needed to model these kinds of events. The AIC is only one possible indicator of the appropriateness of the model, and other criteria should also be taken into account.

INES is only appropriate where hazards are proportional. There will be examples where proportional hazards cannot be assumed e.g. if the survival curves radically diverge or converge [5, 25]. In these circumstances an alternative modelling package should be considered. Guidelines are available elsewhere [10, 12].

In Fig. 2, at 100 months, about 15% of the intervention cohort was predicted to still be alive. Truncated mean survival may underestimate the benefit of treatment. However, in the example shown, the model fails if a longer time horizon is chosen, because the OS probability becomes less than PFS, producing a logical inconsistency which halts the model engine (the screen turns grey when the model engine fails, and INES must be restarted from the run.bat file). This is not a failure of INES as such but an inherent limitation of the PSM framework, by modelling OS and PFS as if they were independent. The literature contains ad-hoc attempts to “correct” the problem, for example, by constraining PFS to be less than OS, or specifying that gains in PFS are automatically translated into equal gains for OS [5, 25]. However, these corrections are not based on principle [25] and we decided that it is more transparent if the model generates an error, rather than give an artificially adjusted result. There may be cases where the model successfully runs for the base case but fails for the univariate sensitivity analyses. If the model fails, the user might choose a shorter time horizon, different parametric survival functions, or a different hazard ratio.

If it is important that the model captures explicitly the relation between PFS and OS, then a different framework would be required, such as a Markov model. Likewise, a PSM supposes that the outcomes (progression and mortality) observed in the source clinical study would be replicated in real-world clinical practice. A PSM is not easily adapted to take account of potential biases in the clinical study, such as unrepresentative selection of patients, inappropriate treatment switching, off-label downstream treatments post-progression, drug wastage, or inappropriate comparator treatments [5].

Because a PSM models PFS and OS independently, an increase in PFS can increase costs (where therapies are given until progression) but does not increase OS in the model (e.g. see the tornado chart, Additional file 5). This is another limitation of the PSM framework, rather than INES per se. The tornado shows that a variation in the HR for OS appears “unbalanced”, in the sense that a given increase in the HR increases the ICER much more than the same unit reduction in the HR reduces the ICER. This occurs because as the HR approaches 1, the absolute difference in life years approaches zero, and hence the ICER approaches infinity. This illustrates a limitation of using the ICER (a ratio) as an outcome variable. Furthermore, if the HR becomes greater than 1, the ICER would become negative, which has no interpretation for decision making. Hence users need to take account of the absolute incremental cost and incremental QALY as well as the ICER when interpreting the results of univariate sensitivity analyses.

There are many ways that a PSM could be configured [5, 12, 18, 19, 25]. We aimed to create a tool for survival analysis and PSM that was easy to use and robust. INES can provide a rapid and transparent analysis that can be shared by all parties, for example facilitating the negotiation of price and reimbursement contracts [26]. It is hoped that the tool will be acceptable in many evaluations, but it will not be suitable for all, and potential users should be aware of its limitations (see Table 3). Further work might include time-varying utilities, budget impact assessment, PSA, and model averaging. As the tool is open-source, it is hoped that a community of users will emerge to comment and modify.

Availability of data and materials

All materials are publically available. The application and code are downloadable from A tutorial dataset is available at Epstein, David (2023), “Tutorial dataset for INES”, Mendeley Data, V1, A manual is available in Spanish from INES is available freely for commercial and non-commercial use under a creative  commons license. The authors are not responsible for any losses arising from the use of this software. 


  1. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health. 2012;15(6):796–803.

    Article  PubMed  Google Scholar 

  2. Green DN. Health Economics R Packages. 2023. Accessed 27 May 2023.

  3. Gimeno-Ballester V, Olry de Labry Lima A, Perez-Troncoso D, Epstein DM. INteractive Model for Extrapolation of Survival and Cost (INES). 2023. Accessed 1 Dec 2022.

  4. Chang W, Cheng J, Allaire J, et al. shiny: Web application framework for R. R package version,. Github.

  5. Woods BS, Sideris E, Palmer S, Latimer N, Soares M. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23(12):1613–21.

    Article  PubMed  Google Scholar 

  6. Rohatgi A. WebPlotDigitizer. 2021. Accessed 5 Oct 2022.

  7. Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21(1):1–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Guyot P, Ades A, Ouwens M, Welton N. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ben-Aharon O, Magnezi R, Leshno M, Goldstein DA. Median survival or mean survival: which measure is the most appropriate for patients, physicians, and policymakers? Oncologist. 2019;24(11):1469–78.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Latimer N. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33:743–54.

    Article  PubMed  Google Scholar 

  11. Latimer N. Nice DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data. Decision Support Unit; 2013.

  12. Woods BS, Sideris E, Palmer S, Latimer N, Soares MO. Nice DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. Decision Support Unit. NICE; 2017.

  13. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–26.

    Article  Google Scholar 

  14. Moore MA, Boardman AE, Vining AR. More appropriate discounting: the rate of social time preference and the value of the social discount rate. J Benefit-Cost Anal. 2013;4(1):1–16.

    Article  CAS  Google Scholar 

  15. Genesis. Guía de Evaluación económica e impacto presupuestario en los informes de evaluación de medicamentos. Guía práctica asociada al programa MADRE 4.0. Published 2016. Accessed 27 Jan 2019.

  16. Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46–58.

    Article  CAS  PubMed  Google Scholar 

  17. Filipovic-Pierucci A, Zarca K, Durand-Zaleski I. Markov models for health economic evaluation modelling in r with the heemod package. Value Health. 2016;19(7):A369–A369.

    Article  Google Scholar 

  18. Jackson CH, Sharples LD, Thompson SG. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction. Int J Biostat. 2010.

    Article  PubMed  Google Scholar 

  19. Jackson CH, Bojke L, Thompson SG, Claxton K, Sharples LD. A framework for addressing structural uncertainty in decision models. Med Decis Making. 2011;31(4):662–74.

    Article  PubMed  Google Scholar 

  20. Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–54.

    Article  PubMed  Google Scholar 

  21. Epstein D. Tutorial dataset for INES. 2023. doi:

  22. Jansen JP. R: Example data for a 4-state partitioned survival model. Accessed 27 May 2023.

  23. Brozek JL, Canelo-Aybar C, Akl EA, et al. GRADE guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—an overview in the context of health decision-making. J Clin Epidemiol. 2021;129:138–50.

    Article  PubMed  Google Scholar 

  24. Negrín MA, Nam J, Briggs AH. Bayesian Solutions for Handling Uncertainty in Survival Extrapolation. Medical Decision Making. 2017;37(4):367-376.

  25. Beca J, Husereau D, Chan KKW, Hawkins N, Hoch JS. Oncology modeling for fun and profit! Key steps for busy analysts in health technology assessment. Pharmacoeconomics. 2018;36(1):7–15.

    Article  PubMed  Google Scholar 

  26. Alkhatib NS, Slack M, Bhattacharjee S, et al. Pricing methods in outcome-based contracting: δ6: adherence-based pricing. J Med Econ. 2020;23(11):1256–65.

    Article  PubMed  Google Scholar 

Download references


The authors are grateful for comments from Miguel Angel Negrín Hernández and other participants on an earlier draft of this paper at the IX Workshop in economic evaluation of the Spanish Health Economics Association, held in Madrid in March 2023 The authors are also grateful for comments received from Victoria Hernández Sanchez, Maria Nieves Sanchíz de la Infiesta, Claudia González Fraga, Carlos Martín Saborido, and Dolores Fraga Fuentes. Any errors are those of the authors.


There were no sources of funding.

Author information

Authors and Affiliations



Each author made substantial contributions to the creation of new software used in the work and have drafted the work or substantively revised it, have approved the submitted version, and have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Corresponding author

Correspondence to David Epstein.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Data entry sheet for the price and posology of daratumumab in the ANDROMEDA trial in the progression-free state for a maximum of 24 treatment cycles of 4 weeks each.

Additional file 2.

Resource use and unit costs.

Additional file 3.

Model predictions of Progression Free Survival, Post-Progression Survival and deaths.

Additional file 4.

Undiscounted and discounted results of the model over a time horizon of 100 months.

Additional file 5.

Tornado chart showing the effect of changes in parameters on the incremental cost-effectiveness ratio.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gimeno-Ballester, V., Perez-Troncoso, D., Olry-Labry, A. et al. INES: Interactive tool for construction and extrapolation of partitioned survival models. Cost Eff Resour Alloc 21, 48 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: